NASDAQ: AKTSAktis Oncology Inc Stock Ownership - Who owns Aktis Oncology?
Insider buying vs selling
Have Aktis Oncology Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Akos Czibere | Med | 2026-09-23 | 5,099 | $20.20 | $102.97kSell |
| Akos Czibere | Med | 2026-09-23 | 12,500 | $4.95 | $61.88kBuy |
| Akos Czibere | Med | 2026-09-23 | 7,401 | $21.03 | $155.65kSell |
| Ken Herrmann | Director | 2026-07-20 | 3,506 | $24.56 | $86.11kSell |
| Ken Herrmann | Director | 2026-07-20 | 3,506 | $0.08 | $280.48Buy |
| Ken Herrmann | Director | 2026-07-20 | 1,350 | $24.56 | $33.16kSell |
| Ken Herrmann | Director | 2026-07-20 | 1,350 | $1.91 | $2.58kBuy |
| Ken Herrmann | Director | 2026-07-17 | 3,065 | $25.21 | $77.26kSell |
| Ken Herrmann | Director | 2026-07-17 | 3,065 | $0.08 | $245.20Buy |
| Akos Czibere | Chief Medical Officer | 2026-07-08 | 50,000 | $4.95 | $247.50kBuy |
AKTS insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when AKTS insiders and whales buy or sell their stock.
AKTS Shareholders
What type of owners hold Aktis Oncology Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Ansbert Gadicke | 18.45% | 10,260,064 | $164.26M | Insider |
| Mpm Bioventures 2018 LP | 18.45% | 10,260,064 | $164.26M | Insider |
| Lilly Co Eli | 11.41% | 6,344,114 | $101.57M | Insider |
| Todd Foley | 7.61% | 4,235,403 | $67.81M | Insider |
| Ecor1 Capital LLC | 0.62% | 347,305 | $5.56M | Insider |
| Vida Ventures II LLC | 0.28% | 157,387 | $2.52M | Insider |
| Helen Susan Kim | 0.28% | 157,387 | $2.52M | Insider |
| Paul L. Feldman | 0.26% | 144,568 | $2.31M | Insider |
| Matthew Roden | 0.17% | 91,998 | $1.47M | Insider |
| Lloyd Mitchell Segal | 0.04% | 19,631 | $314.29k | Insider |
AKTS vs Biotech Stocks
Aktis Oncology Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.